Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease

Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease

New data show brain-volume preservation correlates with patient outcomes Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral...

New data show brain-volume preservation correlates with patient outcomes Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI1 control group a… [+7271 chars]
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease - FHMnews